Investment Rating - The report maintains an "Outperform" rating for the company, indicating a positive outlook compared to market performance [8]. Core Insights - The company has shown a consistent upward trend in quarterly performance, benefiting from the semiconductor industry's expansion and the recovery of helium prices. The ongoing projects are expected to contribute to steady revenue growth [6][8]. - The semiconductor sector is experiencing a significant capital expenditure cycle, with the company positioned to benefit from new projects and increased demand for its gas supply services [8]. - The company has successfully enhanced its supply chain capabilities and is expanding its market share in helium, which is crucial for its growth strategy [8]. Financial Data and Earnings Forecast - Total revenue is projected to grow from 24.24 billion yuan in 2025 to 30.56 billion yuan in 2026, reflecting a year-on-year growth rate of 26.1% [7]. - The net profit attributable to the parent company is expected to increase from 2.86 billion yuan in 2025 to 4.56 billion yuan in 2026, with a significant growth rate of 59.7% [7]. - The company's earnings per share (EPS) is forecasted to rise from 0.22 yuan in 2025 to 0.35 yuan in 2026, indicating a positive trend in profitability [7].

Investment Rating - The report maintains a rating of "Outperform" for the company [1] Core Insights - The company is experiencing steady growth in CMP polishing liquid market share and rapid expansion in functional wet chemicals, leading to high annual performance growth [1] - The semiconductor industry is on an upward trend, with increased demand for materials driven by high wafer fab utilization rates, benefiting the company's product lines [6] - The company has successfully expanded its product offerings in CMP polishing liquids and functional wet chemicals, with significant sales growth in advanced packaging and etching post-cleaning solutions [6] Financial Data and Profit Forecast - Total revenue is projected to reach 25.05 billion yuan in 2025, representing a year-on-year growth of 36.5% [5] - Net profit attributable to shareholders is expected to be 7.95 billion yuan in 2025, with a year-on-year increase of 48.9% [5] - The company anticipates a gross margin of 56.8% in 2025, with a return on equity (ROE) of 23.8% [5] - The projected earnings per share (EPS) for 2025 is 4.70 yuan, with a price-to-earnings (PE) ratio of 57 [5]

Investment Rating - The report assigns a "Strong Buy" rating to the company, Starry Technology, with a target price of 99.3 CNY based on a projected 80x PE for 2026 [3][9]. Core Insights - Starry Technology is positioned as a global leader in visual AI SoC, with significant market share in various segments, including security, robotics, and automotive applications. The company has established a comprehensive product portfolio and is expanding into new AIoT scenarios [6][7][18]. - The demand for edge AI SoC is experiencing explosive growth, driven by advancements in large language models and multimodal models, leading to increased penetration in various applications [40][43]. - The company has a strong competitive advantage due to its self-developed ISP and NPU technologies, which enhance imaging quality and energy efficiency, as well as its integrated SoC platform that combines perception, computation, and connectivity [6][7][24]. Summary by Sections Section 1: Global Leader in Visual AI SoC - Starry Technology, founded in 2017, has rapidly gained a leading position in the visual AI SoC market, achieving significant milestones in product development and market penetration [13][15]. - The company has successfully transitioned from a focus on security electronics to a broader AIoT landscape, with applications in smart security, smart homes, and smart vehicles [18][22]. Section 2: Edge AI SoC Penetration and 3D Sensing Technology - The global market for visual AI SoC is expected to grow significantly, with a compound annual growth rate (CAGR) of 20.0% from 2024 to 2029, driven by increasing demand for edge AI applications [43]. - Starry Technology is actively developing 3D sensing technologies, integrating them with existing AI SoC solutions to meet market demands for high-precision applications [24]. Section 3: Multi-Scene Growth in AI SoC - The company is expanding its presence in multiple sectors, including security, IoT, and automotive, with a notable increase in revenue from these segments [33]. - Starry Technology's revenue from smart IoT and automotive sectors is growing rapidly, indicating a diversification of its business model beyond traditional security applications [33]. Section 4: Financial Projections - The company is projected to achieve a net profit of 256 million CNY in 2024, with significant growth expected in subsequent years, reaching 681 million CNY by 2027 [2][9]. - The financial outlook reflects a robust growth trajectory, supported by high R&D investment and a focus on innovation [31][38].

业绩简评 2026 年 1 月 29 日，公司发布 2025 年业绩预告，公司预计 2025 年 实现归母净利润 70-84 亿元，与上年同期（按合并完成后重述口 径）相比，增加 27.8-41.8 亿元，同比增加约 65.89%至 99.07%， 业绩显著改善。 经营分析 行业基本面近期边际改善，新造船价格回升，中国造船全球份额 提升。根据克拉克森，2025 年 12 月全球新船价格指数达 184.65， 环比+0.17%，是 25 年 7 月份以来首次实现月度环比提升。此外， 从订单量上看，25 年 12 月全球新接订单 2488.5 万 DWT，中国新 接订单 2153.3 万 DWT，新接订单全球份额达 86.5%，环比 11 月提 升 20.1pcts，中国造船竞争力提升。 行业周期持续上行，公司订单饱满，叠加前期高价船陆续交付，看 好公司未来利润率持续提升。我们认为本轮船舶周期仍处于上行 阶段，全球造船产能供不应求，同时叠加 2025 年低基数因素，2026 年全球造船订单有望实现量价齐升。公司作为全球造船龙头，在手 订单充足。2025 年 12 月 8 日，公司实际控制人中国船舶集团与中 国远洋 ...

Investment Rating - The investment rating for the company is "Buy" and is maintained [15] Core Insights - The report indicates that the company maintains its leading position in the industry during periods of volatility, undergoing deep reforms to enhance product and service capabilities, establishing a long-term competitive edge based on open and transparent supplier relationships [5][13] - As store closures and adjustments come to an end, the company has entered a phase of refined and detailed operations, which is expected to boost revenue and release profit elasticity [5][13] Industry Overview - From 2020 to 2025, the supermarket industry faces challenges due to weak demand and intensified competition, leading to declining revenues. The core issue is to boost income, with the industry currently in a loss-reduction phase [9][23] - Online retail penetration is stabilizing between 25%-30%, and rental levels for shops in major cities are expected to decrease by over 20% from 2021 to 2025 [9][32] - The average store efficiency for supermarkets is projected to be 27.77 million yuan in 2024, and the average employee efficiency is expected to be 1.25 million yuan, reflecting significant improvements in operational capabilities [9][32] Company Review - The company is a leading domestic hypermarket that has deeply participated in the rapid transformation of the retail industry over the past 20 years, with a solid foundation in management experience and brand recognition [10][39] - The company has completed its national layout, with strong brand awareness and a robust supply chain, and is now focusing on quality retail reforms to adapt to the inevitable trend of shifting from product "richness" to "value for money" [10][63] Quality Reform - The company is undergoing a quality retail reform initiated in May 2024, which includes internal promotions and external recruitment to quickly build a core management team [11][40] - The company aims to enhance its private label development, targeting a penetration rate of 30%-40% for its private brands by 2025, focusing on safety and health in ingredients and processes [12][58] Investment Recommendation - The report expresses optimism about the company's growth potential through its quality-focused transformation, expecting improvements in revenue stability and profitability from 2025 to 2027, with projected EPS of -0.24, 0.07, and 0.15 yuan respectively [13][15]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected price increase of over 15% in the next 6-12 months [5]. Core Insights - The acquisition of a 51.55% stake in Tefu International is expected to significantly enhance the company's net profit attributable to shareholders, with Tefu's projected revenue for 2025 at 8.187 billion RMB and net profit at 1.474 billion RMB [3]. - The company plans to invest 94.72 million USD (approximately 660 million RMB) in a new float glass project in Ghana, which is expected to have a production capacity of 600 tons per day [3]. - The lithium carbonate segment is projected to benefit from rising prices, with the price reaching 172,000 RMB per ton as of January 28, 2026, leading to a significant recovery in profitability for this segment [4]. Financial Projections - The company’s net profit attributable to shareholders is forecasted to be 1.554 billion RMB in 2025, 3.135 billion RMB in 2026, and 3.810 billion RMB in 2027, with corresponding P/E ratios of 18, 9, and 7 times [5]. - Revenue is expected to grow from 9.696 billion RMB in 2023 to 22.342 billion RMB in 2027, reflecting a compound annual growth rate (CAGR) of approximately 29.96% from 2024 to 2025 [10]. - The diluted earnings per share (EPS) is projected to increase from 0.525 RMB in 2024 to 1.986 RMB in 2027 [10].

4 季度盈利拐点出现，预计高阶智驾产品将 成为新的增长点 核心观点 盈利预测与投资建议 资料来源：公司数据. 东方证券研究所预测. 每股收益使用最新股本全面摊薄计算. 经纬恒润-W 688326.SH 公司研究 | 动态跟踪 | | 买入（维持） | | --- | --- | | 股价（2026年01月29日） | 147.3 元 | | 目标价格 | 213.21 元 | | 52 周最高价/最低价 | 163.68/65.5 元 | | 总股本/流通 A 股（万股） | 11,996/11,162 | | A 股市值（百万元） | 17,670 | | 国家/地区 | 中国 | | 行业 | 汽车与零部件 | | 报告发布日期 | 2026 年 01 月 29 日 | ⚫ 预测 2025-2027 年 EPS 分别为 0.79、3.09、4.98 元（原为 0.30、2.21、3.50 元， 调整收入、毛利率及费用率等），维持可比公司 26 年 PE 平均估值 69 倍，目标价 213.21 元，维持买入评级。 风险提示 乘用车行业销量低于预期、汽车电子业务配套量低于预期、研发及解决方案业务低于预 期、 ...

Investment Rating - The investment rating for the company is "Outperform the Market" (maintained) [1][6]. Core Views - The company has been continuously promoting liability-side business and value transformation, significantly improving product structure and channel value rates. Recent easing of real estate risks is favorable for further valuation enhancement [2][15]. - The company is expected to maintain its earnings forecast for 2025 to 2027, with projected EPS of 7.72, 8.57, and 9.26 CNY per share, respectively. The current stock price corresponds to P/EV ratios of 0.77, 0.69, and 0.63 [2][15]. - The company is anticipated to have a clear valuation recovery space, with an expected annual growth rate of approximately 11% in EV over the next three years, suggesting a reasonable P/EV valuation range of 1.02 to 1.13 [2][15]. Summary by Sections Business Transformation - The company is shifting from a scale-oriented approach to a value-oriented strategy, reducing the proportion of low-value short-term savings products and focusing on long-term protection and savings products. The integration of "insurance + services" enhances customer stickiness and premium capabilities [3][7]. - As of mid-2025, the company has served over 13 million customers in health management, with home care services covering 85 cities and nearly 210,000 customers qualifying for home care services [3]. Channel Development - The company is implementing deep reforms in its sales channels, focusing on high-quality development. The agent channel has seen a 17% increase in new business value, with a 21.6% increase in per capita new business value [9][13]. - The company is expanding its bancassurance channel and other innovative channels, with bancassurance new business value growth reaching 168.6%, ranking among the top in the industry [9][13]. Real Estate Policy Impact - Recent regulatory changes have eased constraints on real estate financing, which is expected to improve market expectations regarding the quality of insurance capital's real estate exposure. This is likely to drive valuation recovery for companies like Ping An [14][15].

Investment Rating - Investment rating: Buy (maintained) [1] Core Views - The company reported a stable performance in 2025, with a revenue of 4.22 billion yuan, a year-on-year decrease of 4.87%, while the net profit attributable to shareholders increased by 14.96% to 906 million yuan [3][4] - The company has implemented effective cost reduction and efficiency enhancement measures, leading to a continuous improvement in profitability [4] - The fourth quarter of 2025 saw a significant profit growth, with a net profit of 223 million yuan, up 44.81% year-on-year, despite a revenue decline of 12.09% [5] Financial Performance Summary - For 2025, the company achieved a revenue of 4.22 billion yuan, a decrease of 4.87% year-on-year, and a net profit of 906 million yuan, an increase of 14.96% [4][9] - The projected revenues for 2025, 2026, and 2027 are 4.22 billion yuan, 4.60 billion yuan, and 5.02 billion yuan, respectively, with expected year-on-year growth rates of -4.9%, 9.1%, and 9.1% [9] - The net profit for the same years is projected to be 906 million yuan, 977 million yuan, and 1.11 billion yuan, with year-on-year growth rates of 14.9%, 7.8%, and 13.6% [9] - The gross margin is expected to improve from 65.2% in 2025 to 66.2% in 2027 [12] Strategic Development - The company is focusing on a "big single product, strong category" development strategy, continuously enhancing brand building [6][7] - The company has rebranded to "China Resources Jiangzhong," further strengthening brand recognition and market influence [8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company is expected to achieve a net profit attributable to shareholders of 1.2 to 1.3 billion yuan in 2025, marking a turnaround from losses, with a similar range for the net profit excluding non-recurring items [3] - The company has made significant improvements in profitability, with a notable focus on cost management and efficiency enhancement [3] - The company has a diverse portfolio of proprietary traditional Chinese medicine products, with 17 patents covering 8 major clinical disease systems [4] - The company is progressing well in its research and development of traditional Chinese medicine, with several new drug applications accepted for review [4] - The company has successfully launched a new chemical drug, the Anilofin injection, which provides a new treatment option for postoperative pain [5] Financial Performance Summary - The company forecasts revenues of 8.03 billion yuan in 2025, 9.11 billion yuan in 2026, and 10.5 billion yuan in 2027, representing year-on-year growth rates of 23.3%, 13.4%, and 15.3% respectively [6] - The net profit attributable to the parent company is projected to be 1.228 billion yuan in 2025, 1.428 billion yuan in 2026, and 1.65 billion yuan in 2027, with a year-on-year growth of 16.2% and 15.5% [6] - The gross margin is expected to improve from 50.2% in 2024 to 52.9% in 2027 [6] - The company’s return on equity (ROE) is projected to recover from -7.1% in 2024 to 11.4% in 2027 [6] Research and Development Progress - The company has a clear development strategy with multiple innovative drug candidates in clinical stages, including treatments for acute myeloid leukemia and ischemic stroke [5] - The company is focusing on expanding its product offerings in respiratory, endocrine, digestive, gynecological, and pediatric diseases [4]